SlideShare una empresa de Scribd logo
1 de 10
Progressive supranuclear palsy
進行性核上麻痺
PSP; Steele-Richardson-Olszewski disease
成人発症の神経変性疾患;
早期からの姿勢不安定性, 垂直方向の核上性注視麻痺を特徴とする
臨床症状は特徴的であり, 眼は “Mona Lisa” stareと呼ばれ, 瞬きは少ない(0-4回/min).
頸部は後屈し, 声量は低下して不明瞭なうなり声に聞こえる.
動作は緩慢で, 後方に転倒しやすい.
下方視が困難であり, 嚥下機能も低下するため, 食事をよくこぼすようになる.
認知能も緩慢になるため, 返答や会話が遅くなる
複視や視野のぼやけ, 羞明,
不随意の眼瞼閉鎖は初期から出現する症状であり,
しばしば眼科を受診する.
多系統萎縮症と異なり, 著名な起立性低血圧は稀
This review provides an update on progressive supranuclear
palsy (PSP, or Steele-Richardson-Olszewski disease), an
adult-onset neurodegenerative disorder characterised by
early postural instability, which leads to falls, and a vertical
supranuclear-gaze palsy. Recent epidemiological studies
have shown that the disorder is more common than previously
recognised, that it is commonly misdiagnosed, and that it may
present to a wide range of hospital specialists. The diagnosis
of PSP hinges on clinical acumen. Attempts to identify a
suitable biomarker in the CSF or a specific and sensitive
imaging or neurophysiological technique have so far failed to
have a significant effect on the diagnostic process. Better
understanding of the molecular pathology of PSP has
highlighted the importance of tau-protein accumulation and
tau-genotype susceptibility in its pathogenesis. No drug
treatment significantly and consistently benefits patients, and
ReviewProgressive supranuclear palsy
Progressive supranuclear palsy:
where are we now?
David J Burn and Andrew J Lees
Lancet Neurology 2002;1:359-69
PSPの疫学
頻度は報告により様々.
年々増加しており, 3-14/100000とされる.
後発年齢は60-65yrであり, 男女差は無し.
発症∼診断までの平均期間は3.6-4.9yrと診断がつかないことが多い
発症∼死亡までの平均期間は5.8-5.9yr程度.
初期診断で挙げられるものはParkinson’s disease(30%), Balance disorder(20%),
 Stroke(10%), Depression(7%)が多い.
初期よりしっかりとPSPと診断される例は43%しかない.
PSPの診断
Possible PSP
Mandatory inclusion criteria
徐々に増悪する症状, 発症は>=40yr, 発症から1yr以内に垂直性の核上性注視麻痺,
垂直方向のSaccade運動の緩慢, 姿勢不安定性の出現を認める.
Mandatory exclusion criteria
最近の脳炎, alien limb syndrome, cortical sensory deficits, focal frontal/temporoparietal atrophy,
Hallucination, ドパミン治療と関係のないdelusion, Alzheimerタイプの認知症, early
cerebellar symptom, 説明困難なautonomic dysautonomiaの既往
Supportive features
左右対称のAkinesia/rigidity (近位優位), 頸位の異常(後方),
LevodopaによるParkinsonism改善が乏しい, 早期の嚥下, 構音障害, 早期の認知症
無為, 思考の緩慢, 停止, 会話の減少, Frontal release signs
Probable PSP
Mandatory inclusion criteria
徐々に増悪する症状, 発症は>=40yr, 発症から1yr以内に垂直性の核上性注視麻痺,
垂直方向のSaccade運動の緩慢, 姿勢不安定性の出現を認める.
Definite PSP
Mandatory inclusion criteria 臨床的にProbable, Possible PSPであり, 組織所見でもPSPに矛盾しない
非典型的な症状も早期から認められる場合がある
片側性のDystonia, 上腕の浮動, 観念運動失行, 口蓋ミオクローヌスなど
PSP-CとPSP-P
PSPには古典的なRichardson’s syndromeを呈するtype(Classical),
Parkinsonismを早期から伴うtypeを認める.
101名の病理的に診断されたPSPのうち, 54%がPSP-C, 32%がPSP-P. 14%が分類不能.
Brain (2005), 128, 1247–1258
PSP-C PSP-P P値 PSP-C PSP-P P値
転倒 85.7% 0% <0.001 100% 80.6% 0.001
認知障害 50.0% 0 <0.001 90.7% 51.6% <0.001
振戦 9.8% 39.1% 0.007 13.0% 43.8% 0.002
構音障害 32.5% 26.1% 0.406 90.2% 81.3% 0.242
嚥下障害 2.7% 4.3% 0.624 75.5% 56.3% 0.070
視覚障害 23.1% 4.3% 0.051 56.6% 34.4% 0.047
左右非対称性の発症 17.9% 45.0% 0.030
動作緩慢 75.6% 73.9% 0.880 98.2% 96.9% 0.685
固縮 39.5% 52.5% 0.333 98.1% 96.8% 0.687
姿勢反射障害 84.4% 7.7% <0.001 100% 96% 0.142
Extra-axial dystonia 0 8.7% 0.138 21.2% 42.4% 0.054
Supranuclear gaze palsy 70.0% 0 0.002 100% 71.4% <0.001
追視, saccade異常 63.6% 0 0.017
錐体路徴候 7.9% 4.3% 0.513 17.0% 15.6% 0.561
Levodopaへの反応性あり 14.3% 50.0% 0.005 1.9% 6.3% 0.323
早期 晩期
PSP-Pの発症早期では
古典的なPSP症状は認められない
転倒, 認知障害が乏しく,
晩期に出現する経過をとる.
PSPでも様々な経過をとる.
PSPの検査
MRI所見
臨床的にPSPと診断された患者の70%がMRIで所見を認める.
中脳の直径(矢状断)<17mm, 中脳が高信号を呈する,
赤核の高信号 or 萎縮, 淡蒼球の高信号.
T2強調画像で淡蒼球が高信号に写る; Myelinated fibreの減少とAstrocytosisの増加,
その周辺の鉄沈着により低信号域を伴い, “eye of the tiger sign” と呼ばれる.
これはHallervorden-Spatz syndromeで有名な所見.
中脳-橋の矢状断面積
PSP患者21名, PD患者23名, MSA-P患者25名, Control 31名の
Prospective Case-control study. (Neurology 2005;64:2050-5)
MRI矢状断にて, 中脳-橋面積比を比較.
2本の補助線; 橋前上部のnotch - 四丘板と
 それに平行となるような橋後下部のnotchを通る線
その線で区切られる中脳, 橋の面積を測定し,
比を各疾患で評価.
Outcome;
中脳面積のみでみると, MSA-PとのOverlapがあるが,
中脳/橋 面積比ではPSPが群を抜いて低い. → 診断法として有用かも?
ただし, Reference Standardが不明, またValidationも無し
Group 中脳面積(mm2) 中脳/橋 比
PSP 56[33-66] 0.124[0.09-0.15]
PD 103[86-136] 0.208[0.17-0.3]
MSA-P 97.2[64-130] 0.266[0.18-0.49]
Control 117.7[101-169] 0.236[0.18-0.32]
PSP 33名, PD 108名, MSA-P 19名, 健常人 50名のProspective study
T1-WIにて, 橋断面積/中脳断面積 (P/M), MCP-width/SCP-width ratioを評価し,
MR Parkinsonism Index = P/M x MCP/SCP を評価.
(MCP; Middle cerebellar peduncles, 中小脳脚, SCP; Superior cerebellar peduncles, 上小脳脚)
Radiology 2008;246:214-21
Figure 2
Figure 2: Sagittal and coronal T1-weighted volumetric spoiled gradient-echo MR images (15.2/6.8; section thickness, 0.6 mm; frequency- and phase-encoding ma-
trix, 256ϫ 256; flip angle, 15°) show midbrain area(1), pons area(2), MCP width(3), and SCP width(4) in (a) a control participant and(b) a patient with PSP. Images
show marked atrophy of both midbrain and SCP in the PSP patient in comparison with the healthy control participant. In the patient with PSP, values wereas follows:
midbrain area, 60 mm2
; pons area, 502 mm2
; MCP width, 8.15 mm; and SCP width, 1.70 mm. In the control participant, values were as follows: midbrain area, 108 mm2
;
pons area, 478 mm2
; MCP width, 10.05 mm; and SCP width, 4.10 mm.
NEURORADIOLOGY:MR Parkinsonism Index for Differentiation of Diseases Quattrone et al
1) 中脳断面積, 2) 橋断面積, 3) 中小脳脚幅, 4) 上小脳脚幅
a)は健常人, b)はPSP患者
各パラメータ
MR Parkinsonism Index
Cutoffと感度, 特異度.
Radiology 2008;246:214-21was smaller than that in patients with
PD (P Ͻ .001) and in control partici-
pants (P Ͻ .001) (Fig 3). No difference,
however, was observed between pa-
tients with PD and control participants.
There was some overlap of individual
values among all groups (Fig 3). There
was no significant difference between
patients with possible PSP and patients
with probable PSP.
Sensitivity, specificity, and PPV of
MCP/SCP for differentiating patients
with PSP from those with PD, patients
with PSP from those with MSA-P, and
patients with PSP from control partici-
pants varied at different cutoff levels
(Table 4), and the optimal levels were
2.69 or greater, 2.43 or greater, and
2.69 or greater, respectively.
MR parkinsonism index values.—
Patients with PSP showed the highest
MR parkinsonism index values with re-
spect to all other groups (patients with
PSP vs patients with MSA-P, P Ͻ .001;
patients with PSP vs patients with PD,
P Ͻ .001; patients with PSP vs control
participants, P Ͻ .001) (Fig 3). There
was no overlap of individual values for
the MR parkinsonism index between
the patients with PSP (median, 19.42;
Table 2
Measurements for Brain Structures in Patients with PSP, MSA-P, and PD and Control
Participants
Group
Midbrain Area
(mm2
)
Pons Area
(mm2
)
SCP Width
(mm)
MCP Width
(mm)
PSP patients (n ϭ 33) 63 (38–94) 406 (230–516) 2.4 (1.6–3.3) 7.0 (5.1–9.4)
MSA-P patients (n ϭ 19) 110 (63–132) 343 (244–492) 2.9 (1.9–3.9) 5.9 (3.4–7.7)
PD patients (n ϭ 108) 119 (70–163) 471 (372–615) 3.7 (3.0–4.8) 8.7 (8.1–10.2)
Control participants (n ϭ 50) 122 (94–168) 469 (386–622) 3.8 (3.1–4.5) 8.8 (8.1–10.5)
Note.—Values are medians, and numbers in parentheses are ranges. For all measurements, P Ͻ .001 (Kruskal-Wallis test).
Table 3
Pairwise Comparisons between Groups
Group Comparison
Midbrain Area
P Value
Pons Area
P Value
SCP Width
P Value
MCP Width
P Value
PSP patients vs MSA-P patients Ͻ.001 .013 .001 .022
PSP patients vs PD patients Ͻ.001 Ͻ.001 Ͻ.001 Ͻ.001
PSP patients vs control participants Ͻ.001 Ͻ.001 Ͻ.001 Ͻ.001
MSA-P patients vs PD patients NS Ͻ.001 Ͻ.001 Ͻ.001
MSA-P patients vs control participants .019 Ͻ.001 Ͻ.001 Ͻ.001
PD patients vs control participants NS NS NS NS
Possible PSP patients vs probable PSP patients .003 NS Ͻ.001 .018
Note.—P values were determined with Mann-Whitney U test, with Bonferroni correction. NS ϭ not significant.
218 Radiology: Volume 246: Number 1—January 2008
strated that 6% of patients with PSP had a
P/M that overlapped with the P/M of con-
trol participants, a finding that was consis-
tent with our findings.
Pathologic evidence has also dem-
onstrated the atrophy of SCPs in pa-
tients with PSP (1,17), whereas atrophy
of MCPs has been found in patients with
MSA (19). Results in recent MR imaging
studies have confirmed these pathologic
observations in both diseases. Atrophy
of the SCPs has been shown on volumet-
ric MR images in patients with PSP
(15), and decreased width of MCPs re-
cently has been demonstrated on mid-
sagittal MR images in patients with MSA
(20). On this basis, in our study we
measured the width of both SCPs and
MCPs on MR images and also investi-
gated the MCP/SCP. Our data confirm
pathologic findings showing that the
SCP width was significantly smaller in
Table 4
MR Parkinsonism Index for Differentiation of Patients with PSP from Patients with PD
and MSA-P and Control Participants
Cutoff and Statistical Values
MR Parkinsonism
Index Value
MCP/SCP
Value
P/M
Value
PSP patients vs PD patients
Cutoff value Ն13.55 Ն2.69 Ն4.88
Sensitivity (%) 100 78.8 90.9
Specificity (%) 100 88.9 93.5
PPV (%) 100 68.4 81.1
PSP patients vs MSA-P patients
Cutoff value Ն12.85 Ն2.43 Ն4.62
Sensitivity (%) 100 93.9 97.0
Specificity (%) 100 89.5 94.7
PPV (%) 100 93.9 97.0
PSP patients vs control participants
Cutoff value Ն13.58 Ն2.69 Ն4.65
Sensitivity (%) 100 78.8 97.0
Specificity (%) 100 88.0 94.0
PPV (%) 100 81.2 91.4
Note.—Optimal cutoff values were determined by using receiver operating characteristic curve analysis.
NEURORADIOLOGY:MRParkinsonismIndexforDifferentiationofDiseases Quattroneetal
45名の疾患が確定していないParkinsonismを呈する患者を対象.
MRIにてMRPIを評価し, Cutoff ≥ 13.55を基準に2群に分類.
その後2年間評価し, PSP診断基準をどの程度満たすかを評価.
MRPI ≥13.55 を満たすのが15名, MRPI <13.55が30名.
28.4±11.7moフォローし, MRPI≥13.55群では11/15でPSPの診断基準を満たし,
MRPI<13.55群でPSPの基準を満たしたのは0例.
MRPI≥13.55は, 感度100%, 特異度90.3%でPSPを診断.
MRPIのProspective cohort
Neurology® 2011;77:1042–1047

Más contenido relacionado

La actualidad más candente

第3回 「頭痛」
第3回 「頭痛」第3回 「頭痛」
第3回 「頭痛」清水 真人
 
診断研究のメタアナリシスをやってみる(みたい)。
診断研究のメタアナリシスをやってみる(みたい)。診断研究のメタアナリシスをやってみる(みたい)。
診断研究のメタアナリシスをやってみる(みたい)。Takashi Fujiwara
 
質的変数の相関・因子分析
質的変数の相関・因子分析質的変数の相関・因子分析
質的変数の相関・因子分析Mitsuo Shimohata
 
進行性核上性麻痺の一例
進行性核上性麻痺の一例進行性核上性麻痺の一例
進行性核上性麻痺の一例TeruKamogashira
 
めまい パート1 鑑別
めまい パート1 鑑別めまい パート1 鑑別
めまい パート1 鑑別NEURALGPNETWORK
 
精神症状の理解とアセスメント④
精神症状の理解とアセスメント④精神症状の理解とアセスメント④
精神症状の理解とアセスメント④Kana Aizawa
 
地域での脳梗塞治療について【ADVANCED】
地域での脳梗塞治療について【ADVANCED】地域での脳梗塞治療について【ADVANCED】
地域での脳梗塞治療について【ADVANCED】NEURALGPNETWORK
 
2014年5月21日「パーティクルフィルタの癖から知るロボットへの確率的手法の正しい適用方法」---第58回システム制御情報学会研究発表講演会チュートリアル講演
2014年5月21日「パーティクルフィルタの癖から知るロボットへの確率的手法の正しい適用方法」---第58回システム制御情報学会研究発表講演会チュートリアル講演2014年5月21日「パーティクルフィルタの癖から知るロボットへの確率的手法の正しい適用方法」---第58回システム制御情報学会研究発表講演会チュートリアル講演
2014年5月21日「パーティクルフィルタの癖から知るロボットへの確率的手法の正しい適用方法」---第58回システム制御情報学会研究発表講演会チュートリアル講演Ryuichi Ueda
 
精神症状の理解とアセスメント①
精神症状の理解とアセスメント①精神症状の理解とアセスメント①
精神症状の理解とアセスメント①Kana Aizawa
 
Introduction to statistics
Introduction to statisticsIntroduction to statistics
Introduction to statisticsKohta Ishikawa
 
操作変数法の書き方_田淵貴大
操作変数法の書き方_田淵貴大操作変数法の書き方_田淵貴大
操作変数法の書き方_田淵貴大Takahiro Tabuchi
 
Rによるlm関数を使わない回帰と梃子比・cookの距離
Rによるlm関数を使わない回帰と梃子比・cookの距離 Rによるlm関数を使わない回帰と梃子比・cookの距離
Rによるlm関数を使わない回帰と梃子比・cookの距離 wada, kazumi
 
精神症状の理解とアセスメント⑦
精神症状の理解とアセスメント⑦精神症状の理解とアセスメント⑦
精神症状の理解とアセスメント⑦Kana Aizawa
 

La actualidad más candente (20)

第3回 「頭痛」
第3回 「頭痛」第3回 「頭痛」
第3回 「頭痛」
 
診断研究のメタアナリシスをやってみる(みたい)。
診断研究のメタアナリシスをやってみる(みたい)。診断研究のメタアナリシスをやってみる(みたい)。
診断研究のメタアナリシスをやってみる(みたい)。
 
Parkinson plus
Parkinson plusParkinson plus
Parkinson plus
 
MSA ethics
MSA ethicsMSA ethics
MSA ethics
 
認知症講座
認知症講座認知症講座
認知症講座
 
علوم - الصف الثامن - ورقة عمل 14 - أنواع المرايا (المستوية)
علوم - الصف الثامن - ورقة عمل 14 - أنواع المرايا (المستوية)علوم - الصف الثامن - ورقة عمل 14 - أنواع المرايا (المستوية)
علوم - الصف الثامن - ورقة عمل 14 - أنواع المرايا (المستوية)
 
CBD PSP update
CBD PSP updateCBD PSP update
CBD PSP update
 
質的変数の相関・因子分析
質的変数の相関・因子分析質的変数の相関・因子分析
質的変数の相関・因子分析
 
進行性核上性麻痺の一例
進行性核上性麻痺の一例進行性核上性麻痺の一例
進行性核上性麻痺の一例
 
めまい パート1 鑑別
めまい パート1 鑑別めまい パート1 鑑別
めまい パート1 鑑別
 
精神症状の理解とアセスメント④
精神症状の理解とアセスメント④精神症状の理解とアセスメント④
精神症状の理解とアセスメント④
 
地域での脳梗塞治療について【ADVANCED】
地域での脳梗塞治療について【ADVANCED】地域での脳梗塞治療について【ADVANCED】
地域での脳梗塞治療について【ADVANCED】
 
2014年5月21日「パーティクルフィルタの癖から知るロボットへの確率的手法の正しい適用方法」---第58回システム制御情報学会研究発表講演会チュートリアル講演
2014年5月21日「パーティクルフィルタの癖から知るロボットへの確率的手法の正しい適用方法」---第58回システム制御情報学会研究発表講演会チュートリアル講演2014年5月21日「パーティクルフィルタの癖から知るロボットへの確率的手法の正しい適用方法」---第58回システム制御情報学会研究発表講演会チュートリアル講演
2014年5月21日「パーティクルフィルタの癖から知るロボットへの確率的手法の正しい適用方法」---第58回システム制御情報学会研究発表講演会チュートリアル講演
 
インフルエンザ
インフルエンザインフルエンザ
インフルエンザ
 
精神症状の理解とアセスメント①
精神症状の理解とアセスメント①精神症状の理解とアセスメント①
精神症状の理解とアセスメント①
 
めまい 中枢 Vs 末梢
めまい 中枢 Vs 末梢めまい 中枢 Vs 末梢
めまい 中枢 Vs 末梢
 
Introduction to statistics
Introduction to statisticsIntroduction to statistics
Introduction to statistics
 
操作変数法の書き方_田淵貴大
操作変数法の書き方_田淵貴大操作変数法の書き方_田淵貴大
操作変数法の書き方_田淵貴大
 
Rによるlm関数を使わない回帰と梃子比・cookの距離
Rによるlm関数を使わない回帰と梃子比・cookの距離 Rによるlm関数を使わない回帰と梃子比・cookの距離
Rによるlm関数を使わない回帰と梃子比・cookの距離
 
精神症状の理解とアセスメント⑦
精神症状の理解とアセスメント⑦精神症状の理解とアセスメント⑦
精神症状の理解とアセスメント⑦
 

Destacado

Progressive supranuclear palsy presentation
Progressive supranuclear palsy presentationProgressive supranuclear palsy presentation
Progressive supranuclear palsy presentationDr. Md. Rashedul Islam
 
Case record...Progressive supranuclear palsy
Case record...Progressive supranuclear palsyCase record...Progressive supranuclear palsy
Case record...Progressive supranuclear palsyProfessor Yasser Metwally
 
Supranuclear pathways and lesions
Supranuclear pathways and lesionsSupranuclear pathways and lesions
Supranuclear pathways and lesionsLaxmi Eye Institute
 
Parálisis supranuclear progresiva
Parálisis supranuclear progresivaParálisis supranuclear progresiva
Parálisis supranuclear progresivaFrancisco Ortega
 
PSP - Personal Software Process
PSP - Personal Software ProcessPSP - Personal Software Process
PSP - Personal Software ProcessRafael Queiroz
 
Paralisis Supranuclear Progresiva cambios-clínicopatológicos
Paralisis Supranuclear Progresiva cambios-clínicopatológicosParalisis Supranuclear Progresiva cambios-clínicopatológicos
Paralisis Supranuclear Progresiva cambios-clínicopatológicosComunidad Cetram
 
ER査読会:肺塞栓症を除外するための 年齢調整された d dimerカットオフ値について
ER査読会:肺塞栓症を除外するための 年齢調整された d dimerカットオフ値についてER査読会:肺塞栓症を除外するための 年齢調整された d dimerカットオフ値について
ER査読会:肺塞栓症を除外するための 年齢調整された d dimerカットオフ値について小滝 和也
 
免疫グロブリン遊離鎖 κ/λ比
免疫グロブリン遊離鎖 κ/λ比免疫グロブリン遊離鎖 κ/λ比
免疫グロブリン遊離鎖 κ/λ比Katsushige Takagishi
 
Deep brain stimulation
Deep brain stimulationDeep brain stimulation
Deep brain stimulationamudha mary
 

Destacado (20)

A Case of Progressive Supranuclear Palsy
A Case of Progressive Supranuclear PalsyA Case of Progressive Supranuclear Palsy
A Case of Progressive Supranuclear Palsy
 
Progressive supranuclear palsy presentation
Progressive supranuclear palsy presentationProgressive supranuclear palsy presentation
Progressive supranuclear palsy presentation
 
Case record...Progressive supranuclear palsy
Case record...Progressive supranuclear palsyCase record...Progressive supranuclear palsy
Case record...Progressive supranuclear palsy
 
熱中症
熱中症熱中症
熱中症
 
Msa
MsaMsa
Msa
 
好中球減少性発熱
好中球減少性発熱好中球減少性発熱
好中球減少性発熱
 
伝染性単核症
伝染性単核症伝染性単核症
伝染性単核症
 
Supranuclear pathways and lesions
Supranuclear pathways and lesionsSupranuclear pathways and lesions
Supranuclear pathways and lesions
 
Slide show...Progressive supranuclear palsy
Slide show...Progressive supranuclear palsySlide show...Progressive supranuclear palsy
Slide show...Progressive supranuclear palsy
 
Eppark psp
Eppark pspEppark psp
Eppark psp
 
Parálisis supranuclear progresiva
Parálisis supranuclear progresivaParálisis supranuclear progresiva
Parálisis supranuclear progresiva
 
PSP - Personal Software Process
PSP - Personal Software ProcessPSP - Personal Software Process
PSP - Personal Software Process
 
Paralisis Supranuclear Progresiva cambios-clínicopatológicos
Paralisis Supranuclear Progresiva cambios-clínicopatológicosParalisis Supranuclear Progresiva cambios-clínicopatológicos
Paralisis Supranuclear Progresiva cambios-clínicopatológicos
 
結膜炎 JAMA 2013
結膜炎 JAMA 2013結膜炎 JAMA 2013
結膜炎 JAMA 2013
 
Presentation parkinson
Presentation parkinsonPresentation parkinson
Presentation parkinson
 
強皮症腎クリーゼ
強皮症腎クリーゼ強皮症腎クリーゼ
強皮症腎クリーゼ
 
ER査読会:肺塞栓症を除外するための 年齢調整された d dimerカットオフ値について
ER査読会:肺塞栓症を除外するための 年齢調整された d dimerカットオフ値についてER査読会:肺塞栓症を除外するための 年齢調整された d dimerカットオフ値について
ER査読会:肺塞栓症を除外するための 年齢調整された d dimerカットオフ値について
 
免疫グロブリン遊離鎖 κ/λ比
免疫グロブリン遊離鎖 κ/λ比免疫グロブリン遊離鎖 κ/λ比
免疫グロブリン遊離鎖 κ/λ比
 
DLB Dementia with Lewy bodies
DLB Dementia with Lewy bodiesDLB Dementia with Lewy bodies
DLB Dementia with Lewy bodies
 
Deep brain stimulation
Deep brain stimulationDeep brain stimulation
Deep brain stimulation
 

Similar a PSP

NEUROIMAGING IN PARKINSONISM edited.pptx
NEUROIMAGING IN PARKINSONISM edited.pptxNEUROIMAGING IN PARKINSONISM edited.pptx
NEUROIMAGING IN PARKINSONISM edited.pptxvijay prakash
 
MSA Multiple System Atrophy
MSA Multiple System AtrophyMSA Multiple System Atrophy
MSA Multiple System AtrophyLucaBaldelli
 
Electrophysiological assessment of optic neuritis: is there still a role
Electrophysiological assessment of optic neuritis: is there still a roleElectrophysiological assessment of optic neuritis: is there still a role
Electrophysiological assessment of optic neuritis: is there still a roleClare Fraser
 
Neuroradiology in dementia
Neuroradiology in dementiaNeuroradiology in dementia
Neuroradiology in dementiaNeurologyKota
 
Optic coherence tomography
Optic coherence tomographyOptic coherence tomography
Optic coherence tomographyNeurologyKota
 
Vocal fold motion impairment an early sign in msa clinical case 29-04-2021
Vocal fold motion impairment an early sign in msa clinical case 29-04-2021Vocal fold motion impairment an early sign in msa clinical case 29-04-2021
Vocal fold motion impairment an early sign in msa clinical case 29-04-2021MotezKhadhraoui
 
Ben Turner - MRI workshop
Ben Turner -  MRI workshopBen Turner -  MRI workshop
Ben Turner - MRI workshopMS Trust
 
Somatosensory evoked potentials
Somatosensory evoked potentialsSomatosensory evoked potentials
Somatosensory evoked potentialsManideep Malaka
 
Visual Outcome After Cataract Surgery In Patients With Retinitis Pigmentosa.
Visual Outcome After Cataract Surgery In Patients With  Retinitis Pigmentosa.Visual Outcome After Cataract Surgery In Patients With  Retinitis Pigmentosa.
Visual Outcome After Cataract Surgery In Patients With Retinitis Pigmentosa.Dr. Jagannath Boramani
 
Optic Neuritis and OCT in Multiple Sclerosis
Optic Neuritis and OCT in Multiple Sclerosis Optic Neuritis and OCT in Multiple Sclerosis
Optic Neuritis and OCT in Multiple Sclerosis neurophq8
 
Atypical parkinsonism
Atypical parkinsonismAtypical parkinsonism
Atypical parkinsonismSarath Menon
 
Ocular Ultrasound: Techniques, Evidence, Pathology
Ocular Ultrasound: Techniques, Evidence, PathologyOcular Ultrasound: Techniques, Evidence, Pathology
Ocular Ultrasound: Techniques, Evidence, Pathologydpark419
 
Multiple Myeloma.pptx
Multiple Myeloma.pptxMultiple Myeloma.pptx
Multiple Myeloma.pptxkezias7
 
Brainstem auditory evoked responses (baer or abr
Brainstem auditory evoked responses (baer or abrBrainstem auditory evoked responses (baer or abr
Brainstem auditory evoked responses (baer or abrDaria Otgonbayar
 
Novel approach to diagnosis of mycobacterial and bacterial
Novel approach to diagnosis of mycobacterial and bacterialNovel approach to diagnosis of mycobacterial and bacterial
Novel approach to diagnosis of mycobacterial and bacterialNeurologyKota
 
Utilidad strain en cardiopatia isquemica
Utilidad strain en cardiopatia isquemica Utilidad strain en cardiopatia isquemica
Utilidad strain en cardiopatia isquemica Ricardo Mora MD
 

Similar a PSP (20)

pòster-anglès-ok2
pòster-anglès-ok2pòster-anglès-ok2
pòster-anglès-ok2
 
NEUROIMAGING IN PARKINSONISM edited.pptx
NEUROIMAGING IN PARKINSONISM edited.pptxNEUROIMAGING IN PARKINSONISM edited.pptx
NEUROIMAGING IN PARKINSONISM edited.pptx
 
Mehta.ppt
Mehta.pptMehta.ppt
Mehta.ppt
 
MSA Multiple System Atrophy
MSA Multiple System AtrophyMSA Multiple System Atrophy
MSA Multiple System Atrophy
 
Electrophysiological assessment of optic neuritis: is there still a role
Electrophysiological assessment of optic neuritis: is there still a roleElectrophysiological assessment of optic neuritis: is there still a role
Electrophysiological assessment of optic neuritis: is there still a role
 
Neuroradiology in dementia
Neuroradiology in dementiaNeuroradiology in dementia
Neuroradiology in dementia
 
Optic coherence tomography
Optic coherence tomographyOptic coherence tomography
Optic coherence tomography
 
Vocal fold motion impairment an early sign in msa clinical case 29-04-2021
Vocal fold motion impairment an early sign in msa clinical case 29-04-2021Vocal fold motion impairment an early sign in msa clinical case 29-04-2021
Vocal fold motion impairment an early sign in msa clinical case 29-04-2021
 
Ben Turner - MRI workshop
Ben Turner -  MRI workshopBen Turner -  MRI workshop
Ben Turner - MRI workshop
 
Somatosensory evoked potentials
Somatosensory evoked potentialsSomatosensory evoked potentials
Somatosensory evoked potentials
 
Visual Outcome After Cataract Surgery In Patients With Retinitis Pigmentosa.
Visual Outcome After Cataract Surgery In Patients With  Retinitis Pigmentosa.Visual Outcome After Cataract Surgery In Patients With  Retinitis Pigmentosa.
Visual Outcome After Cataract Surgery In Patients With Retinitis Pigmentosa.
 
Optic Neuritis and OCT in Multiple Sclerosis
Optic Neuritis and OCT in Multiple Sclerosis Optic Neuritis and OCT in Multiple Sclerosis
Optic Neuritis and OCT in Multiple Sclerosis
 
Atypical parkinsonism
Atypical parkinsonismAtypical parkinsonism
Atypical parkinsonism
 
Optovue Poster
Optovue PosterOptovue Poster
Optovue Poster
 
Ocular Ultrasound: Techniques, Evidence, Pathology
Ocular Ultrasound: Techniques, Evidence, PathologyOcular Ultrasound: Techniques, Evidence, Pathology
Ocular Ultrasound: Techniques, Evidence, Pathology
 
Multiple Myeloma.pptx
Multiple Myeloma.pptxMultiple Myeloma.pptx
Multiple Myeloma.pptx
 
Brainstem auditory evoked responses (baer or abr
Brainstem auditory evoked responses (baer or abrBrainstem auditory evoked responses (baer or abr
Brainstem auditory evoked responses (baer or abr
 
Novel approach to diagnosis of mycobacterial and bacterial
Novel approach to diagnosis of mycobacterial and bacterialNovel approach to diagnosis of mycobacterial and bacterial
Novel approach to diagnosis of mycobacterial and bacterial
 
Updates in ms
Updates  in msUpdates  in ms
Updates in ms
 
Utilidad strain en cardiopatia isquemica
Utilidad strain en cardiopatia isquemica Utilidad strain en cardiopatia isquemica
Utilidad strain en cardiopatia isquemica
 

Más de Katsushige Takagishi (20)

高齢者の掻痒感
高齢者の掻痒感高齢者の掻痒感
高齢者の掻痒感
 
Microvascular angina
Microvascular anginaMicrovascular angina
Microvascular angina
 
SLEと妊娠
SLEと妊娠SLEと妊娠
SLEと妊娠
 
Cryoglobulinemia
CryoglobulinemiaCryoglobulinemia
Cryoglobulinemia
 
Fulminant type 1 dm
Fulminant type 1 dmFulminant type 1 dm
Fulminant type 1 dm
 
Crps
CrpsCrps
Crps
 
Whipple病
Whipple病Whipple病
Whipple病
 
真性多血症 本態性血小板増多症
真性多血症 本態性血小板増多症真性多血症 本態性血小板増多症
真性多血症 本態性血小板増多症
 
肝膿瘍
肝膿瘍肝膿瘍
肝膿瘍
 
血小板 Itp
血小板 Itp血小板 Itp
血小板 Itp
 
正常圧水頭症
正常圧水頭症正常圧水頭症
正常圧水頭症
 
好酸球増多
好酸球増多好酸球増多
好酸球増多
 
Pneumocystis carinii
Pneumocystis cariniiPneumocystis carinii
Pneumocystis carinii
 
Migraine aura without headache
Migraine aura without headacheMigraine aura without headache
Migraine aura without headache
 
気管軟化症 EDAC
気管軟化症 EDAC気管軟化症 EDAC
気管軟化症 EDAC
 
脂肪塞栓
脂肪塞栓脂肪塞栓
脂肪塞栓
 
卵円孔開存
卵円孔開存卵円孔開存
卵円孔開存
 
間質性膀胱炎
間質性膀胱炎間質性膀胱炎
間質性膀胱炎
 
TTP HUSについて
TTP HUSについてTTP HUSについて
TTP HUSについて
 
名称未設定
名称未設定名称未設定
名称未設定
 

Último

5 Moments of Everyday Self-Loathing That Perfectly Describe Your Life
5 Moments of Everyday Self-Loathing That Perfectly Describe Your Life5 Moments of Everyday Self-Loathing That Perfectly Describe Your Life
5 Moments of Everyday Self-Loathing That Perfectly Describe Your LifeSalty Vixen Stories & More
 
"Quest for Knowledge: An Exciting Journey Through 40 Brain-Bending Questions ...
"Quest for Knowledge: An Exciting Journey Through 40 Brain-Bending Questions ..."Quest for Knowledge: An Exciting Journey Through 40 Brain-Bending Questions ...
"Quest for Knowledge: An Exciting Journey Through 40 Brain-Bending Questions ...RAGHURAMYC
 
Holi:: "The Festival of Colors in India"
Holi:: "The Festival of Colors in India"Holi:: "The Festival of Colors in India"
Holi:: "The Festival of Colors in India"IdolsArts
 
Inside Look: Brooke Monk's Exclusive OnlyFans Content Production
Inside Look: Brooke Monk's Exclusive OnlyFans Content ProductionInside Look: Brooke Monk's Exclusive OnlyFans Content Production
Inside Look: Brooke Monk's Exclusive OnlyFans Content Productionget joys
 
Taylor Swift quiz( with answers) by SJU quizzers
Taylor Swift quiz( with answers) by SJU quizzersTaylor Swift quiz( with answers) by SJU quizzers
Taylor Swift quiz( with answers) by SJU quizzersSJU Quizzers
 
Young adult book quiz by SJU quizzers.ppt
Young adult book quiz by SJU quizzers.pptYoung adult book quiz by SJU quizzers.ppt
Young adult book quiz by SJU quizzers.pptSJU Quizzers
 
Carowinds 2024: Thrills, Spills & Surprises
Carowinds 2024: Thrills, Spills & SurprisesCarowinds 2024: Thrills, Spills & Surprises
Carowinds 2024: Thrills, Spills & Surprisescarawinds99
 

Último (7)

5 Moments of Everyday Self-Loathing That Perfectly Describe Your Life
5 Moments of Everyday Self-Loathing That Perfectly Describe Your Life5 Moments of Everyday Self-Loathing That Perfectly Describe Your Life
5 Moments of Everyday Self-Loathing That Perfectly Describe Your Life
 
"Quest for Knowledge: An Exciting Journey Through 40 Brain-Bending Questions ...
"Quest for Knowledge: An Exciting Journey Through 40 Brain-Bending Questions ..."Quest for Knowledge: An Exciting Journey Through 40 Brain-Bending Questions ...
"Quest for Knowledge: An Exciting Journey Through 40 Brain-Bending Questions ...
 
Holi:: "The Festival of Colors in India"
Holi:: "The Festival of Colors in India"Holi:: "The Festival of Colors in India"
Holi:: "The Festival of Colors in India"
 
Inside Look: Brooke Monk's Exclusive OnlyFans Content Production
Inside Look: Brooke Monk's Exclusive OnlyFans Content ProductionInside Look: Brooke Monk's Exclusive OnlyFans Content Production
Inside Look: Brooke Monk's Exclusive OnlyFans Content Production
 
Taylor Swift quiz( with answers) by SJU quizzers
Taylor Swift quiz( with answers) by SJU quizzersTaylor Swift quiz( with answers) by SJU quizzers
Taylor Swift quiz( with answers) by SJU quizzers
 
Young adult book quiz by SJU quizzers.ppt
Young adult book quiz by SJU quizzers.pptYoung adult book quiz by SJU quizzers.ppt
Young adult book quiz by SJU quizzers.ppt
 
Carowinds 2024: Thrills, Spills & Surprises
Carowinds 2024: Thrills, Spills & SurprisesCarowinds 2024: Thrills, Spills & Surprises
Carowinds 2024: Thrills, Spills & Surprises
 

PSP

  • 2. PSP; Steele-Richardson-Olszewski disease 成人発症の神経変性疾患; 早期からの姿勢不安定性, 垂直方向の核上性注視麻痺を特徴とする 臨床症状は特徴的であり, 眼は “Mona Lisa” stareと呼ばれ, 瞬きは少ない(0-4回/min). 頸部は後屈し, 声量は低下して不明瞭なうなり声に聞こえる. 動作は緩慢で, 後方に転倒しやすい. 下方視が困難であり, 嚥下機能も低下するため, 食事をよくこぼすようになる. 認知能も緩慢になるため, 返答や会話が遅くなる 複視や視野のぼやけ, 羞明, 不随意の眼瞼閉鎖は初期から出現する症状であり, しばしば眼科を受診する. 多系統萎縮症と異なり, 著名な起立性低血圧は稀 This review provides an update on progressive supranuclear palsy (PSP, or Steele-Richardson-Olszewski disease), an adult-onset neurodegenerative disorder characterised by early postural instability, which leads to falls, and a vertical supranuclear-gaze palsy. Recent epidemiological studies have shown that the disorder is more common than previously recognised, that it is commonly misdiagnosed, and that it may present to a wide range of hospital specialists. The diagnosis of PSP hinges on clinical acumen. Attempts to identify a suitable biomarker in the CSF or a specific and sensitive imaging or neurophysiological technique have so far failed to have a significant effect on the diagnostic process. Better understanding of the molecular pathology of PSP has highlighted the importance of tau-protein accumulation and tau-genotype susceptibility in its pathogenesis. No drug treatment significantly and consistently benefits patients, and ReviewProgressive supranuclear palsy Progressive supranuclear palsy: where are we now? David J Burn and Andrew J Lees Lancet Neurology 2002;1:359-69
  • 4. PSPの診断 Possible PSP Mandatory inclusion criteria 徐々に増悪する症状, 発症は>=40yr, 発症から1yr以内に垂直性の核上性注視麻痺, 垂直方向のSaccade運動の緩慢, 姿勢不安定性の出現を認める. Mandatory exclusion criteria 最近の脳炎, alien limb syndrome, cortical sensory deficits, focal frontal/temporoparietal atrophy, Hallucination, ドパミン治療と関係のないdelusion, Alzheimerタイプの認知症, early cerebellar symptom, 説明困難なautonomic dysautonomiaの既往 Supportive features 左右対称のAkinesia/rigidity (近位優位), 頸位の異常(後方), LevodopaによるParkinsonism改善が乏しい, 早期の嚥下, 構音障害, 早期の認知症 無為, 思考の緩慢, 停止, 会話の減少, Frontal release signs Probable PSP Mandatory inclusion criteria 徐々に増悪する症状, 発症は>=40yr, 発症から1yr以内に垂直性の核上性注視麻痺, 垂直方向のSaccade運動の緩慢, 姿勢不安定性の出現を認める. Definite PSP Mandatory inclusion criteria 臨床的にProbable, Possible PSPであり, 組織所見でもPSPに矛盾しない 非典型的な症状も早期から認められる場合がある 片側性のDystonia, 上腕の浮動, 観念運動失行, 口蓋ミオクローヌスなど
  • 5. PSP-CとPSP-P PSPには古典的なRichardson’s syndromeを呈するtype(Classical), Parkinsonismを早期から伴うtypeを認める. 101名の病理的に診断されたPSPのうち, 54%がPSP-C, 32%がPSP-P. 14%が分類不能. Brain (2005), 128, 1247–1258 PSP-C PSP-P P値 PSP-C PSP-P P値 転倒 85.7% 0% <0.001 100% 80.6% 0.001 認知障害 50.0% 0 <0.001 90.7% 51.6% <0.001 振戦 9.8% 39.1% 0.007 13.0% 43.8% 0.002 構音障害 32.5% 26.1% 0.406 90.2% 81.3% 0.242 嚥下障害 2.7% 4.3% 0.624 75.5% 56.3% 0.070 視覚障害 23.1% 4.3% 0.051 56.6% 34.4% 0.047 左右非対称性の発症 17.9% 45.0% 0.030 動作緩慢 75.6% 73.9% 0.880 98.2% 96.9% 0.685 固縮 39.5% 52.5% 0.333 98.1% 96.8% 0.687 姿勢反射障害 84.4% 7.7% <0.001 100% 96% 0.142 Extra-axial dystonia 0 8.7% 0.138 21.2% 42.4% 0.054 Supranuclear gaze palsy 70.0% 0 0.002 100% 71.4% <0.001 追視, saccade異常 63.6% 0 0.017 錐体路徴候 7.9% 4.3% 0.513 17.0% 15.6% 0.561 Levodopaへの反応性あり 14.3% 50.0% 0.005 1.9% 6.3% 0.323 早期 晩期 PSP-Pの発症早期では 古典的なPSP症状は認められない 転倒, 認知障害が乏しく, 晩期に出現する経過をとる. PSPでも様々な経過をとる.
  • 6. PSPの検査 MRI所見 臨床的にPSPと診断された患者の70%がMRIで所見を認める. 中脳の直径(矢状断)<17mm, 中脳が高信号を呈する, 赤核の高信号 or 萎縮, 淡蒼球の高信号. T2強調画像で淡蒼球が高信号に写る; Myelinated fibreの減少とAstrocytosisの増加, その周辺の鉄沈着により低信号域を伴い, “eye of the tiger sign” と呼ばれる. これはHallervorden-Spatz syndromeで有名な所見.
  • 7. 中脳-橋の矢状断面積 PSP患者21名, PD患者23名, MSA-P患者25名, Control 31名の Prospective Case-control study. (Neurology 2005;64:2050-5) MRI矢状断にて, 中脳-橋面積比を比較. 2本の補助線; 橋前上部のnotch - 四丘板と  それに平行となるような橋後下部のnotchを通る線 その線で区切られる中脳, 橋の面積を測定し, 比を各疾患で評価. Outcome; 中脳面積のみでみると, MSA-PとのOverlapがあるが, 中脳/橋 面積比ではPSPが群を抜いて低い. → 診断法として有用かも? ただし, Reference Standardが不明, またValidationも無し Group 中脳面積(mm2) 中脳/橋 比 PSP 56[33-66] 0.124[0.09-0.15] PD 103[86-136] 0.208[0.17-0.3] MSA-P 97.2[64-130] 0.266[0.18-0.49] Control 117.7[101-169] 0.236[0.18-0.32]
  • 8. PSP 33名, PD 108名, MSA-P 19名, 健常人 50名のProspective study T1-WIにて, 橋断面積/中脳断面積 (P/M), MCP-width/SCP-width ratioを評価し, MR Parkinsonism Index = P/M x MCP/SCP を評価. (MCP; Middle cerebellar peduncles, 中小脳脚, SCP; Superior cerebellar peduncles, 上小脳脚) Radiology 2008;246:214-21 Figure 2 Figure 2: Sagittal and coronal T1-weighted volumetric spoiled gradient-echo MR images (15.2/6.8; section thickness, 0.6 mm; frequency- and phase-encoding ma- trix, 256ϫ 256; flip angle, 15°) show midbrain area(1), pons area(2), MCP width(3), and SCP width(4) in (a) a control participant and(b) a patient with PSP. Images show marked atrophy of both midbrain and SCP in the PSP patient in comparison with the healthy control participant. In the patient with PSP, values wereas follows: midbrain area, 60 mm2 ; pons area, 502 mm2 ; MCP width, 8.15 mm; and SCP width, 1.70 mm. In the control participant, values were as follows: midbrain area, 108 mm2 ; pons area, 478 mm2 ; MCP width, 10.05 mm; and SCP width, 4.10 mm. NEURORADIOLOGY:MR Parkinsonism Index for Differentiation of Diseases Quattrone et al 1) 中脳断面積, 2) 橋断面積, 3) 中小脳脚幅, 4) 上小脳脚幅 a)は健常人, b)はPSP患者
  • 9. 各パラメータ MR Parkinsonism Index Cutoffと感度, 特異度. Radiology 2008;246:214-21was smaller than that in patients with PD (P Ͻ .001) and in control partici- pants (P Ͻ .001) (Fig 3). No difference, however, was observed between pa- tients with PD and control participants. There was some overlap of individual values among all groups (Fig 3). There was no significant difference between patients with possible PSP and patients with probable PSP. Sensitivity, specificity, and PPV of MCP/SCP for differentiating patients with PSP from those with PD, patients with PSP from those with MSA-P, and patients with PSP from control partici- pants varied at different cutoff levels (Table 4), and the optimal levels were 2.69 or greater, 2.43 or greater, and 2.69 or greater, respectively. MR parkinsonism index values.— Patients with PSP showed the highest MR parkinsonism index values with re- spect to all other groups (patients with PSP vs patients with MSA-P, P Ͻ .001; patients with PSP vs patients with PD, P Ͻ .001; patients with PSP vs control participants, P Ͻ .001) (Fig 3). There was no overlap of individual values for the MR parkinsonism index between the patients with PSP (median, 19.42; Table 2 Measurements for Brain Structures in Patients with PSP, MSA-P, and PD and Control Participants Group Midbrain Area (mm2 ) Pons Area (mm2 ) SCP Width (mm) MCP Width (mm) PSP patients (n ϭ 33) 63 (38–94) 406 (230–516) 2.4 (1.6–3.3) 7.0 (5.1–9.4) MSA-P patients (n ϭ 19) 110 (63–132) 343 (244–492) 2.9 (1.9–3.9) 5.9 (3.4–7.7) PD patients (n ϭ 108) 119 (70–163) 471 (372–615) 3.7 (3.0–4.8) 8.7 (8.1–10.2) Control participants (n ϭ 50) 122 (94–168) 469 (386–622) 3.8 (3.1–4.5) 8.8 (8.1–10.5) Note.—Values are medians, and numbers in parentheses are ranges. For all measurements, P Ͻ .001 (Kruskal-Wallis test). Table 3 Pairwise Comparisons between Groups Group Comparison Midbrain Area P Value Pons Area P Value SCP Width P Value MCP Width P Value PSP patients vs MSA-P patients Ͻ.001 .013 .001 .022 PSP patients vs PD patients Ͻ.001 Ͻ.001 Ͻ.001 Ͻ.001 PSP patients vs control participants Ͻ.001 Ͻ.001 Ͻ.001 Ͻ.001 MSA-P patients vs PD patients NS Ͻ.001 Ͻ.001 Ͻ.001 MSA-P patients vs control participants .019 Ͻ.001 Ͻ.001 Ͻ.001 PD patients vs control participants NS NS NS NS Possible PSP patients vs probable PSP patients .003 NS Ͻ.001 .018 Note.—P values were determined with Mann-Whitney U test, with Bonferroni correction. NS ϭ not significant. 218 Radiology: Volume 246: Number 1—January 2008 strated that 6% of patients with PSP had a P/M that overlapped with the P/M of con- trol participants, a finding that was consis- tent with our findings. Pathologic evidence has also dem- onstrated the atrophy of SCPs in pa- tients with PSP (1,17), whereas atrophy of MCPs has been found in patients with MSA (19). Results in recent MR imaging studies have confirmed these pathologic observations in both diseases. Atrophy of the SCPs has been shown on volumet- ric MR images in patients with PSP (15), and decreased width of MCPs re- cently has been demonstrated on mid- sagittal MR images in patients with MSA (20). On this basis, in our study we measured the width of both SCPs and MCPs on MR images and also investi- gated the MCP/SCP. Our data confirm pathologic findings showing that the SCP width was significantly smaller in Table 4 MR Parkinsonism Index for Differentiation of Patients with PSP from Patients with PD and MSA-P and Control Participants Cutoff and Statistical Values MR Parkinsonism Index Value MCP/SCP Value P/M Value PSP patients vs PD patients Cutoff value Ն13.55 Ն2.69 Ն4.88 Sensitivity (%) 100 78.8 90.9 Specificity (%) 100 88.9 93.5 PPV (%) 100 68.4 81.1 PSP patients vs MSA-P patients Cutoff value Ն12.85 Ն2.43 Ն4.62 Sensitivity (%) 100 93.9 97.0 Specificity (%) 100 89.5 94.7 PPV (%) 100 93.9 97.0 PSP patients vs control participants Cutoff value Ն13.58 Ն2.69 Ն4.65 Sensitivity (%) 100 78.8 97.0 Specificity (%) 100 88.0 94.0 PPV (%) 100 81.2 91.4 Note.—Optimal cutoff values were determined by using receiver operating characteristic curve analysis. NEURORADIOLOGY:MRParkinsonismIndexforDifferentiationofDiseases Quattroneetal
  • 10. 45名の疾患が確定していないParkinsonismを呈する患者を対象. MRIにてMRPIを評価し, Cutoff ≥ 13.55を基準に2群に分類. その後2年間評価し, PSP診断基準をどの程度満たすかを評価. MRPI ≥13.55 を満たすのが15名, MRPI <13.55が30名. 28.4±11.7moフォローし, MRPI≥13.55群では11/15でPSPの診断基準を満たし, MRPI<13.55群でPSPの基準を満たしたのは0例. MRPI≥13.55は, 感度100%, 特異度90.3%でPSPを診断. MRPIのProspective cohort Neurology® 2011;77:1042–1047